BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 24714775)

  • 1. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
    Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
    Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
    Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High FOXM1 expression was associated with bladder carcinogenesis.
    Liu D; Zhang Z; Kong CZ
    Tumour Biol; 2013 Apr; 34(2):1131-8. PubMed ID: 23325617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer.
    Song BN; Kim SK; Chu IS
    Exp Mol Med; 2017 Jan; 49(1):e282. PubMed ID: 28082741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
    Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
    Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results.
    Mares J; Szakacsova M; Soukup V; Duskova J; Horinek A; Babjuk M
    Neoplasma; 2013; 60(3):295-301. PubMed ID: 23452234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer.
    Liu A; Zeng S; Lu X; Xiong Q; Xue Y; Tong L; Xu W; Sun Y; Zhang Z; Xu C
    Int J Biol Macromol; 2019 Feb; 123():322-334. PubMed ID: 30414902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
    Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
    Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.
    Lee JS; Leem SH; Lee SY; Kim SC; Park ES; Kim SB; Kim SK; Kim YJ; Kim WJ; Chu IS
    J Clin Oncol; 2010 Jun; 28(16):2660-7. PubMed ID: 20421545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.